Board summary
Key figures
39,128
Registered population
53.1% aged 18–64
30.8%
Aged 65+
ICB 21.9% · England 17.9%
3.4%
Ethnic minority (non-White)
1.1% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 9.2% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
7,086
Hypertension register
+6.01% in 3 yrs · England +5.60%
309
SMI register
25.4% of Chichester's
704
COPD register
Reviews -2.49% in 3 yrs
Forecast to 2030
8,406
Hypertension patients, 2030
+1,320 on today
80.3%
QRISK ≥20% on statins, 2030
+8.00pp over 3 yrs
7.7%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma annual review coverage trails benchmarks.
Reviews reached 64.4% (Chichester 67.5%, England 65.7%), leaving about 950 of 2,666 patients unreviewed, which may reflect recall capacity to test locally.
High-risk lipid therapy below England rate.
Despite +15.2% three-year growth, lipid therapy for QRISK ≥ 20% is 60.5% against 63.6% in England, which could reflect recall gaps to audit.
Strong hypertension control and heart failure reviews.
Hypertension treatment to target is 73.0% (England 70.3%) and annual heart failure reviews reach 90.6% (Chichester 82.2%, England 78.5%).
Population, age and ethnicity
Patients aged 65 and over comprise 30.8% of the registered list, exceeding benchmarks
Rural North Chichester PCN registers 39,128 patients. Across the network, 30.8% (12,062 patients) are aged 65 and over, exceeding Chichester (26.9%), NHS Sussex Integrated Care Board (21.9%), and England (17.9%). Patients aged 0-17 comprise 16.0% (6,273 patients; Chichester 17.3%, NHS Sussex Integrated Care Board 17.7%, England 19.6%). Based on Census usual residents rather than GP registrations, 96.7% are White, above Chichester (95.4%), NHS Sussex Integrated Care Board (91.0%), and England (81.1%), with a 3.4% ethnic minority share.
Age profile
65+: ICB 21.9%, England 17.9%
Ethnicity
Older people · falls rows are Chichester local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Chichester LA) | 2,453 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 79.2% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 64.0% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Chichester LA) | 1,285 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Chichester LA) | 8.7 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Zero registered patients live in Core20 areas, with an average IMD decile of 6.7
Rural North Chichester PCN records 0.0% of registered patients in the Core20 cohort (Chichester 0.0%, NHS Sussex Integrated Care Board 9.2%, England 21.0%). Its average IMD decile is 6.7 (Chichester 6.2, NHS Sussex Integrated Care Board 6.1, England 5.5). All four practices—The Petworth Surgery, Pulborough Medical Group, Loxwood Surgery, and Riverbank Medical Centre—record a 0.0% Core20 share (0 estimated patients). Average IMD deciles are 5.5 at The Petworth Surgery and 7.6 at Pulborough Medical Group. Zero Core20 concentration means outreach must address dispersed rural vulnerability directly.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
309
SMI register
0.78% recorded prevalence
172
Learning disability register
0.44% recorded prevalence
11
Care homes, 465 beds
In the PCN catchment
8.5%
Provide unpaid care
Chichester, Census 2021
The PCN records 309 severe mental illness patients (0.8%; Chichester 1.0%, NHS Sussex Integrated Care Board 1.1%, England 1.0%) and 172 learning disability patients (0.4%; Chichester 0.6%, NHS Sussex Integrated Care Board 0.6%, England 0.6%). Catchment facilities include 11 care homes with 465 beds. Lower learning disability prevalence than benchmarks could reflect coding or case-mix differences to test through practice register audits.
Severe mental illness: physical health checks
Annual SMI blood pressure checks reached 85.7% (England 83.4%) and BMI checks 86.5% (England 82.1%). Three-year blood pressure gains (+2.6 pp) trailed England (+4.4 pp) across 309 patients. Proactive recall is needed to sustain physical health monitoring.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,086
Hypertension register
+6.01%
Register growth, 3 yrs
Chichester +5.87% · England +5.60%
+5.73pp
BP control, under 80
≤140/90 · +1.87pp aged 80+
+1,320
More patients by 2030
Forecast 8,406 (20.23%)
Hypertension case-finding and control
Hypertension prevalence is 18.0% (7,086 patients), above Chichester (17.4%), NHS Sussex ICB (16.3%) and England (15.2%). Blood pressure treated to target reaches 73.0% (England 70.3%), and heart failure reviews reach 90.6% (England 78.5%). However, recent blood pressure monitoring is 89.1%, trailing Chichester (91.6%) and England (90.0%), while 3-year change of +1.9% lagged England (+3.6%). Stroke prevalence is 2.5% (976 patients; Chichester 2.5%, England 1.9%), but 3-year change was -0.8% while England changed +2.3%; whether this reflects coding shifts or mortality changes is unverified locally. Trailing monitoring rates alongside high treatment achievement indicate an opportunity to systematise annual blood pressure reviews so controlled patients do not slip from target.
Lipids and statins
Lipid-lowering therapy for patients with QRISK ≥ 20% reaches 60.5%, trailing England (63.6%) despite a +15.2% 3-year change (England +6.2%), while matching Chichester (60.4%). Lower high-risk uptake than England implies an opportunity to prioritise risk-score recall across primary prevention cohorts.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 118,241 | £2.00 | £2.42 | £1.86 | £236,482 |
| Cardiovascular (all), 2025 | 132,697 | £3.47 | £3.32 | £3.33 | £460,459 |
In 2026, lipid-regulating drugs cost £2.00 per item across 118,241 items (England £1.86, Chichester £2.11, NHS Sussex ICB £2.42). Across these items, the PCN spends £16,554 more than at England's unit cost, but £49,661 less than at NHS Sussex Integrated Care Board's unit cost. Higher unit costs than England suggest formulary review could reduce expenditure without compromising lipid-lowering treatment reach.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−0.13%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+0.54%
Asthma prevalence, PCN 3-yr % change
Annual asthma reviews reached 64.4% across 2,666 patients, trailing Chichester (67.5%) and England (65.7%), as three-year progress fell 0.1% (England +4.4%), leaving about 950 patients unreviewed. Second-hand smoke recording for ages 6–19 was 74.1% (England 78.8%). COPD prevalence 3-year change was +7.8% to 704 patients (1.8%), but annual reviews fell 2.5% over three years (England +2.8%), despite current achievement of 77.1%. Stalled reviews and a 3.8 pp drop in smoking cessation support (to 93.7%, England +0.1 pp) could reflect unverified recall capacity constraints.
Cancer register and children's immunisation
Cancer prevalence reached 6.0% (2,370 patients; England 3.8%). In Q1 2025/26 childhood immunisations, age 5 MMR dose 1 reached 95.8% (England 91.7%), but dose 2 dropped to 91.6% across 95 children, falling 3.4 pp below the 95.0% target. At The Petworth Surgery, dose 2 fell 23.1 pp below dose 1 (to 69.2% across 13 children). This pre-school drop-off indicates an opportunity for focused recall before school entry.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
58.5%
Sussex ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,360
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Sussex ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 56.6% | 53.2% | 19% | 1,668 |
| Breast | 86.1% | 85.4% | 23% | 1,400 |
| Bowel | 49.8% | 47.0% | 26% | 1,133 |
| Lung | 30.3% | 33.8% | 15% | 1,058 |
| Skin cancer | 95.3% | 87.8% | 17% | 698 |
In 2022, 58.5% of cancers with a known stage in NHS Sussex ICB (4,799 of 8,209) were diagnosed at stage 1 or 2, above England (55.3%) but 16.5 pp below the 75.0% national ambition by 2028. Closing this gap would require about 1,360 extra early diagnoses annually across the ICB. Staged completeness was 64.3% (8,209 of 12,766 cases; England 67.0%). Early presentation varied from 24.1% for oesophagus to 86.1% for breast. These ICB figures describe system pathways rather than PCN performance. System-level diagnostic shortfalls mean primary care vigilance and early referral remain critical to improving stage distribution.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026, University Hospitals Sussex NHS Foundation Trust achieved 65.2% against the 85.0% 62-day referral to treatment standard, below Royal Surrey NHS Foundation Trust (84.5%), Portsmouth Hospitals University NHS Trust (75.2%), NHS Surrey and Sussex Integrated Care Board (71.5%) and England (71.2%). Its 28-day faster diagnosis standard was 74.0% (England 79.3%). Diagnostic 6-week waits reached 39.3% for colonoscopy and 45.4% for flexi sigmoidoscopy (England 30.8% and 32.1%). Hospital metrics do not measure PCN referral quality. Acute delays and endoscopy backlogs could delay definitive cancer management for referred PCN patients.
| Pathways within standard (%) | Sussex | Royal Surrey | Portsmouth | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 74.01 | 82.62 | 66.81 | 79.29 | 79.32 |
| 31-day treatment (96%) | 76.79 | 96.43 | 94.78 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 65.20 | 84.48 | 75.20 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Sussex | Royal Surrey | Portsmouth | England |
|---|---|---|---|---|
| MRI | 5.62 | 0.00 | 50.36 | 21.40 |
| CT | 8.57 | 0.15 | 13.06 | 9.92 |
| Echocardiography | 0.39 | 1.55 | 32.75 | 28.48 |
| Colonoscopy | 39.35 | 0.00 | 82.52 | 30.83 |
| Gastroscopy | 20.02 | 0.00 | 74.88 | 29.02 |
| All 15 DM01 tests | 12.95 | 8.82 | 51.96 | 23.14 |
| Community services activity | West Sussex residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 78,050 | 309,615 |
| Referrals | 16,015 | 66,930 |
| Patients with a contact | 19,770 | 85,660 |
Community services (residents of West Sussex), Jun 2026 (provisional). In Jun 2026, 72.7% of community service contacts among Chichester residents were with adults aged 65+ (56,740 of 78,050 contacts). These borough resident figures were not captured at PCN level. High community service usage among older people highlights an established network that could support cancer care and rehabilitation locally.
Practice variation and patient experience
Patient satisfaction exceeds England, but phone access varies by 15.0 pp across practices
In 2025/26, QOF overall achievement exceeded England (92.5%) across all four practices, from 92.6% at Pulborough Medical Group to 96.8% at Riverbank Medical Centre. Clinical domain scores reached 95.6% at Pulborough Medical Group to 100.0% at Riverbank Medical Centre, but vaccination and immunisation showed an 18.6 pp spread, from 53.0% at The Petworth Surgery to 71.6% at Riverbank Medical Centre.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Riverbank | 119 | 0.0 | 71.2% | 75.3% | 96.0% |
| Loxwood Surgery | 116 | 0.0 | 75.8% | 76.0% | 92.9% |
| Pulborough | 128 | 0.0 | 66.3% | 72.2% | 89.0% |
| Petworth | 111 | 0.0 | 60.9% | 77.5% | 81.6% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Ten of 25 tracked measures trail England over three years despite treatment control gains
Across 25 tracked measures, 10 trail England's three-year trajectory. Annual review and prevention activities lag most: COPD reviews fell 2.5% (England +2.8%), asthma reviews fell 0.1% (England +4.4%), and smoking cessation offers declined 3.8 pp (England +0.1 pp). In contrast, clinical management achieved strong growth: QRISK ≥ 20% lipid therapy rose 15.2% (England +6.2%), under-80 blood pressure control rose 8.8% (England +3.2%), and heart failure reviews rose 12.7% (England +8.7%). This divergence could reflect clinical prioritisation over routine annual recall, which local appointment audits would test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
COPD reviews
Asthma reviews
Smoking support (SMI)
Stroke register
Breast screening (53-70)
QRISK statin treatment
BP control, under 80
Heart failure reviews
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Chichester | Asset | PCN | Chichester |
|---|---|---|---|---|---|
| Care homes (catchment) | 11 (465 beds) | n/a | Schools (catchment) | 62 | n/a |
| Children's centres | 5 | 6 | Places of worship | 96 | 153 |
| Libraries | 4 | 5 | Homelessness support (VCS) | 0 | no data |
| Day centres (VCS) | 2 | 1 | Carers support groups (VCS) | 1 | 1 |
| Primary schools (LA maintained) | 29 | 31 | Primary academies | 3 | 22 |
| Special schools | 2 | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured annual asthma review recall
64.4% of 2,666 asthma register patients had an annual review, trailing Chichester (67.5%) and England (65.7%), leaving 949 (about 950) unreviewed. For discussion: practices could run structured annual asthma recall using a single template and flexible slots, reviewing inhaler prescribing alongside review completion. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
COPD case-finding and review audit
COPD prevalence is 1.8% (704 of 39,128 patients) vs 1.9% in Chichester and England (gap +37 to +56 patients); annual reviews fell 2.5% over 3 years. For discussion: practices could search for smokers or ex-smokers with repeated respiratory prescribing lacking a COPD code and run structured annual review recall. Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Option 3
Learning disability register validation
Learning disability QOF prevalence is 0.4% (172 of 39,128 patients) versus 0.6% in Chichester and England, a benchmark gap range of +44 to +58 patients. For discussion: practices could audit clinical records for uncoded learning disability diagnoses and cross-check lists where social-care data sharing exists. Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older age capacity review (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Dispersed vulnerability outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI blood pressure recall audit (p4) | Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension monitoring recall audit (p5) | Hypertension patients with a recent blood pressure reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school MMR second-dose recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Early cancer referral audit (p7) | Cancers diagnosed at stage 1 or 2 (All cancer sites) | — | ICB |
| Digital triage and access review (p9) | GPPS easy to contact the practice using its website | 10YHP, hospital to community | Practice |
| Option 1 · Structured annual asthma review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · COPD case-finding and review audit (p12) | Registered population · COPD register · COPD: QOF prevalence | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN |
| Option 3 · Learning disability register validation (p12) | Registered population · Learning disability register · Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
